MedTrace Logo

Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma

NCT02660710 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2022-10-28

No results posted yet for this study

Summary

The purpose of this study is to establish the safety of rituximab plus cyclophosphamide, doxorubicin, vincristine,prednisone (R-CHOP) in HIV-infected and HIV-uninfected diffuse large B-cell lymphoma (DLBCL) patients in Malawi.

Conditions

  • Diffuse Large B-cell Lymphoma
  • HIV

Interventions

DRUG

R-CHOP

maximum of 6-8 cycles of R-CHOP over 18-24 weeks

Sponsors & Collaborators

  • Fogarty International Center of the National Institute of Health

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Matthew Painschab, MD · University of North Carolina

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2021-07-22
Completion
2022-07-22

Countries

  • Malawi

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02660710 on ClinicalTrials.gov